Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
China Medical System Holdings Ltd.
CMS’s (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions
June 8, 2026
CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®
May 23, 2026
CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China
May 23, 2026
CMS(867.HK/8A8.SG): New Drug for Renal Anaemia Desidustat Tablets Approved in China
May 16, 2026
CMS(867.HK/8A8.SG):Ruxolitinib Phosphate Cream (Lumirix®) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
May 16, 2026
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
January 30, 2026